New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
14:43 EDTOMEDOncoMed jumps 7.2% to $38.88
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
12:12 EDTOMEDOncoMed cancer pipeline expanded with new candidate, says Piper Jaffray
Subscribe for More Information
08:37 EDTOMEDOncoMed announces advancement small molecule Wnt pathway inhibitor
Subscribe for More Information
September 29, 2014
07:17 EDTOMEDOncoMed data supports phase 2 ALPINE study of tarextumab
Subscribe for More Information
September 28, 2014
14:23 EDTOMEDOncoMed demcizumab trials show 'encouraging' safety and anti-tumor activity
OncoMed Pharmaceuticals presented safety and efficacy data from two Phase 1b clinical trials of demcizumab in pancreatic cancer and non-small cell lung cancer, NSCLC, at the European Society for Medical Oncology 2014 Congress in Madrid, Spain. Results from the Phase 1b studies demonstrate that demcizumab, in combination with standard-of-care chemotherapy, is well tolerated, especially in patients where the company's risk mitigation, monitoring and truncated dosing strategies have been employed. Encouraging tumor response rates were presented at ESMO from a study of demcizumab with gemcitabine or gemcitabine plus Abraxane in patients with first-line pancreatic cancer, and from the study of demcizumab plus pemetrexed and carboplatin for the first-line treatment of Stage III/IV NSCLC. OncoMed's Phase 1b studies identified the demcizumab dosing schedules for the company's planned randomized Phase 2 proof-of-concept trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use